The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

After a chill week, we’re back to drinking from the firehose. One of the larger, if not sufficiently heralded, wins for the patient advocacy community last year was the effort

I don’t have anything insightful or novel to say about the HHS firings today, but I can’t let the moment go unacknowledged. None of this is good, as evidenced by

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.